作者: Gregory A. Yanik , Stephan A. Grupp , Michael A. Pulsipher , John E. Levine , Kirk R. Schultz
DOI: 10.1016/J.BBMT.2014.09.019
关键词:
摘要: Abstract Idiopathic pneumonia syndrome (IPS) is an acute, noninfectious lung disorder associated with high morbidity and mortality after hematopoietic cell transplantation. Previous studies have suggested a role for TNFα in the pathogenesis of IPS. We report multicenter phase II trial investigating soluble TNF-binding protein, etanercept (Enbrel, Amgen, Thousand Oaks, CA), treatment pediatric patients Eligible were